Carney, M E; Maxwell, G L; Lancaster, J M et al. (1998) Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers. J Soc Gynecol Investig 5:281-5
|
Lancaster, J M; Wiseman, R W; Berchuck, A (1996) An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene. Obstet Gynecol 87:306-9
|
Berchuck, A; Cirisano, F; Lancaster, J M et al. (1996) Role of BRCA1 mutation screening in the management of familial ovarian cancer. Am J Obstet Gynecol 175:738-46
|
Havrilesky, L J; Elbendary, A; Hurteau, J A et al. (1995) Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet Gynecol 85:1007-10
|
Havrilesky, L J; Hurteau, J A; Whitaker, R S et al. (1995) Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta. Cancer Res 55:944-8
|
Hurteau, J; Rodriguez, G C; Whitaker, R S et al. (1994) Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 74:93-9
|
Berchuck, A; Kohler, M F; Marks, J R et al. (1994) The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 170:246-52
|
Berchuck, A; Kohler, M F; Hopkins, M P et al. (1994) Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol 52:232-6
|
Berchuck, A; Elbendary, A; Havrilesky, L et al. (1994) Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1:181-90
|
Kohler, M F; Kerns, B J; Humphrey, P A et al. (1993) Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 81:643-50
|
Showing the most recent 10 out of 11 publications